- Home
- / Immutep
Immutep
Stock Price
$1.9
2024-10-29
Market Capitalization
$282.4 M
2024-10-29
Immutep Summary
Company Summary
- Overview
- Immutep (formerly Prima BioMed) is a biotechnology company focused on developing autoimmune and cancer immunotherapy treatment. It develops therapeutics that modulate lymphocyte activation gene-3, a cell surface molecule that plays a role in regulating T cells.
- Type
- Public
- Status
- Active
- Founded
- 2001
- HQ
- Sydney, AU | view all locations
- Website
- https://www.immutep.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Deanne Miller, Chief Operating Officer, General Counsel & Company Secretary
Christian Mueller, Vice President Strategic Development
James Flinn, Intellectual Property and Innovation Director
LocationsView all
6 locations detected
Sydney, NSW HQ
Australia
level 12/95 Pitt St
Sydney, NSW
Australia
1 Martin Pl
The Rocks, NSW
Australia
Level 12/225 George St
Orsay, IDF
France
2 Rue Jean Rostand
Berlin, Berlin
Germany
Glinkastraße 28
Leipzig, SN
Germany
Deutscher Pl. 5A
Immutep Financials
Summary Financials
- Revenue (H1, 2026)
- $4.1M
- Gross profit (H1, 2026)
- $6.0M
- Net income (H1, 2026)
- ($44.9M)
- Cash (H1, 2026)
- $72.7M
- EBIT (H1, 2026)
- ($46.0M)